We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Wentilactone A Reverses the NF-κB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IκB in Ovarian Cancer Cells.
- Authors
Lv, Cuiting; Ren, Chunxia; Yu, Yinjue; Yin, Huijing; Huang, Caiguo; Yang, Gong; Hong, Yang
- Abstract
Wentilactone A (WA) is a tetranorditerpenoid isolated from marine algae. We previously found that WA inhibited cancer cell proliferation with little toxicity. In this study, we show that high expression of extracellular matrix protein-1 (ECM1) promotes cancer cell cisplatin resistance, and the secreted ECM1 activates normal fibroblasts (NFs) to transform cells with characteristics of cancer-associated fibroblasts (CAFs). Transcription of the ECM1 gene is regulated largely by NF-κB through EP881C/T-EP266C binding sites. WA supresses the phosphorylation of NF-κB through inhibition of the upstream IKK/IκB phoshorylation to block the expression of ECM1, which reverses the cisplatin-induced activation of NF-κB/ECM1. On the contrary, cisplatin facilitates phosphorylation of NF-κB to enhance the expression of ECM1. These results highlight ECM1 as a potential target for treatment of cisplatin-resistant cancers associated with the ECM1 activated signaling. In addition, WA reverses cisplatin resistance by targeting both tumor cells and the tumor microenvironment through IKK/IκB/NF-κB signaling to reduce the expression of the ECM1 protein.
- Subjects
OVARIAN tumors; FIBROBLASTS; ANTINEOPLASTIC agents; CELLULAR signal transduction; CISPLATIN; CELL proliferation; CELL lines; ALGAE; TRANSCRIPTION factors; DRUG resistance in cancer cells; PHOSPHORYLATION; PHARMACODYNAMICS
- Publication
Nutrients, 2022, Vol 14, Issue 18, pN.PAG
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu14183790